JP2019516720A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516720A5 JP2019516720A5 JP2018560597A JP2018560597A JP2019516720A5 JP 2019516720 A5 JP2019516720 A5 JP 2019516720A5 JP 2018560597 A JP2018560597 A JP 2018560597A JP 2018560597 A JP2018560597 A JP 2018560597A JP 2019516720 A5 JP2019516720 A5 JP 2019516720A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- general formula
- group
- ethyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 134
- 125000000217 alkyl group Chemical group 0.000 claims description 35
- 125000005843 halogen group Chemical group 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 229910052799 carbon Inorganic materials 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 claims description 10
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims description 9
- 150000003536 tetrazoles Chemical class 0.000 claims description 9
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 7
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 125000004450 alkenylene group Chemical group 0.000 claims description 4
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 4
- 125000003700 epoxy group Chemical group 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000003827 glycol group Chemical group 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 230000000155 isotopic effect Effects 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 125000006239 protecting group Chemical group 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 3
- 230000029936 alkylation Effects 0.000 claims description 3
- 238000005804 alkylation reaction Methods 0.000 claims description 3
- 150000001540 azides Chemical class 0.000 claims description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000006649 (C2-C20) alkynyl group Chemical group 0.000 claims description 2
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 claims description 2
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 2
- 125000003358 C2-C20 alkenyl group Chemical group 0.000 claims description 2
- 125000004036 acetal group Chemical group 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 230000002152 alkylating effect Effects 0.000 claims description 2
- 125000004419 alkynylene group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- JRZBPELLUMBLQU-UHFFFAOYSA-N carbonazidic acid Chemical compound OC(=O)N=[N+]=[N-] JRZBPELLUMBLQU-UHFFFAOYSA-N 0.000 claims description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- -1 chloro, methyl Chemical group 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002524 organometallic group Chemical group 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000005156 substituted alkylene group Chemical group 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 description 12
- 238000006345 epimerization reaction Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1608777.7A GB201608777D0 (en) | 2016-05-18 | 2016-05-18 | Compounds |
| GB1608777.7 | 2016-05-18 | ||
| PCT/GB2017/051385 WO2017199033A1 (en) | 2016-05-18 | 2017-05-18 | Intermediates for the synthesis of bile acid derivatives, in particular of obeticholic acid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516720A JP2019516720A (ja) | 2019-06-20 |
| JP2019516720A5 true JP2019516720A5 (enExample) | 2020-07-02 |
| JP7034093B2 JP7034093B2 (ja) | 2022-03-11 |
Family
ID=56320629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560597A Active JP7034093B2 (ja) | 2016-05-18 | 2017-05-18 | 胆汁酸誘導体、特に、オベチコール酸の合成のための中間体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10968250B2 (enExample) |
| EP (2) | EP3458469B1 (enExample) |
| JP (1) | JP7034093B2 (enExample) |
| KR (1) | KR102458265B1 (enExample) |
| CN (1) | CN109415407B (enExample) |
| AU (1) | AU2017266539B2 (enExample) |
| EA (1) | EA037584B1 (enExample) |
| ES (2) | ES2970336T3 (enExample) |
| GB (1) | GB201608777D0 (enExample) |
| HR (1) | HRP20211128T1 (enExample) |
| HU (1) | HUE054851T2 (enExample) |
| MX (1) | MX378591B (enExample) |
| PT (1) | PT3458469T (enExample) |
| WO (1) | WO2017199033A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201608776D0 (en) * | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| EP3431486A1 (en) * | 2017-07-18 | 2019-01-23 | Bionice, S.L.U. | Process and intermediates for the synthesis of obeticholic acid and derivatives thereof |
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| CN111138509B (zh) * | 2018-11-02 | 2022-12-06 | 东莞东阳光药物研发有限公司 | 奥贝胆酸的制备方法 |
| CN111072744B (zh) * | 2019-12-03 | 2021-09-14 | 江苏佳尔科药业集团股份有限公司 | 一种以ba为原料合成熊去氧胆酸的方法 |
| CN114315945A (zh) * | 2020-09-28 | 2022-04-12 | 四川澄华生物科技有限公司 | 一种胆甾酸及其衍生物的除杂方法 |
| CN112341516B (zh) * | 2020-11-14 | 2022-07-15 | 湖南科瑞生物制药股份有限公司 | 5,6-环氧类固醇类化合物及其制备方法和应用 |
| ES2978497R1 (es) * | 2021-11-02 | 2025-11-03 | Sandhill One Llc | UDCA de origen no animal de alta pureza |
| GB202416085D0 (en) | 2024-10-31 | 2024-12-18 | Nzp Uk Ltd | Reduction process |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2624748A (en) | 1950-09-09 | 1953-01-06 | Upjohn Co | Bisnorchola-4, 6-dien-3-one-22-al |
| US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| ATE156158T1 (de) | 1992-04-14 | 1997-08-15 | Cornell Res Foundation Inc | Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung |
| AU6392894A (en) | 1993-02-26 | 1994-09-14 | Magainin Pharmaceuticals, Inc. | Chemical synthesis of squalamine |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| DK1392714T3 (da) | 2001-03-12 | 2006-01-09 | Intercept Pharmaceuticals Inc | Steroider som agonister for FXR |
| US20090062256A1 (en) | 2001-06-01 | 2009-03-05 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
| EP1446438A2 (en) | 2001-11-07 | 2004-08-18 | Nektar Therapeutics Al, Corporation | Branched polymers and their conjugates |
| EP1568706A1 (en) | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
| JP2007210888A (ja) * | 2006-01-12 | 2007-08-23 | Mitsubishi Chemicals Corp | ステロイド化合物の製造方法 |
| CN101374854A (zh) * | 2006-01-12 | 2009-02-25 | 三菱化学株式会社 | 甾类化合物的制备方法 |
| CN101395170A (zh) | 2006-02-14 | 2009-03-25 | 英特塞普特药品公司 | 用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物 |
| DK2040713T3 (da) | 2006-06-27 | 2014-09-29 | Intercept Pharmaceuticals Inc | Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande |
| CA2928178C (en) | 2007-01-19 | 2019-09-10 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
| US8796249B2 (en) | 2008-07-30 | 2014-08-05 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
| AU2009316484B2 (en) | 2008-11-19 | 2015-04-16 | Intercept Pharmaceuticals, Inc. | TGR5 modulators and methods of use thereof |
| HUE039171T2 (hu) | 2008-11-19 | 2018-12-28 | Intercept Pharmaceuticals Inc | TGR5 modulátorok és azok alkalmazási eljárása |
| JP2013500986A (ja) | 2009-07-29 | 2013-01-10 | ザ・ユニバーシティ・オブ・シカゴ | 肝臓ｘ受容体アゴニスト |
| ES2822375T3 (es) | 2012-06-19 | 2021-04-30 | Intercept Pharmaceuticals Inc | Preparación de la forma no cristalina del ácido obeticólico |
| NZ707389A (en) | 2012-10-26 | 2018-08-31 | Intercept Pharmaceuticals Inc | Process for preparing bile acid derivatives |
| WO2014085474A1 (en) | 2012-11-28 | 2014-06-05 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
| US20140206657A1 (en) * | 2013-01-18 | 2014-07-24 | City Of Hope | Bile acid analog tgr5 agonists |
| CN105377870B (zh) | 2013-05-14 | 2018-04-03 | 英特塞普特医药品公司 | 作为法尼醇x受体调节剂的胆汁酸的11‑羟基衍生物及其氨基酸共轭物 |
| CA2913108A1 (en) | 2013-05-24 | 2014-11-27 | Nestec S.A. | Pathway specific assays for predicting irritable bowel syndrome diagnosis |
| WO2015183794A1 (en) * | 2014-05-27 | 2015-12-03 | City Of Hope | Tgr5 agonist complexes for treating diabetes and cancer |
| SI3626725T1 (sl) | 2014-05-29 | 2023-04-28 | Bar Pharmaceuticals S.R.L. | Derivati holana za uporabo pri zdravljenju in/ali preprečevanju bolezni, posredovanih s FXR in TGR5/GPBAR1 |
| BR112017009657A2 (pt) | 2014-11-06 | 2018-01-23 | Enanta Pharmaceuticals, Inc | análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos |
| EA033427B1 (ru) | 2014-11-19 | 2019-10-31 | Nzp Uk Ltd | 6-алкил-7-гидрокси-4-ен-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr |
| ES2748692T3 (es) | 2014-11-19 | 2020-03-17 | Nzp Uk Ltd | Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la producción de moduladores FXR de esteroides |
| JP6698085B2 (ja) | 2014-11-19 | 2020-05-27 | エヌゼットピー ユーケー リミテッド | ステロイドＦＸＲモジュレーター製造のための中間体としての６α−アルキル−６，７−ジオン−ステロイド |
| KR102526632B1 (ko) | 2014-11-19 | 2023-04-27 | 엔제트피 유케이 리미티드 | 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 5β-6-알킬-7-하이드록시-3-온 스테로이드 |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| RU2017121457A (ru) | 2014-11-26 | 2018-12-26 | Энанта Фармасьютикалс, Инк. | Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения |
| WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| WO2016086134A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| CN105348365A (zh) * | 2014-12-03 | 2016-02-24 | 四川百利药业有限责任公司 | 一种胆酸衍生物及其制备方法、药物组合物和用途 |
| CN106279328A (zh) | 2015-05-20 | 2017-01-04 | 重庆药友制药有限责任公司 | 一种制备6α-烷基鹅去氧胆酸的方法 |
| TW201700447A (zh) | 2015-06-19 | 2017-01-01 | 英特賽普醫藥品公司 | Tgr5調控劑及其用法 |
| CN106397522A (zh) | 2015-07-31 | 2017-02-15 | 中国人民解放军军事医学科学院毒物药物研究所 | 3,7‑二（叔丁基二甲基硅基氧基）‑6‑烯‑5β‑胆烷‑24‑酸甲酯 |
| CN106478759A (zh) | 2015-08-31 | 2017-03-08 | 陕西合成药业股份有限公司 | 奥贝胆酸衍生物及其制备方法和用途 |
| CN106478756A (zh) | 2015-09-02 | 2017-03-08 | 中美华世通生物医药科技（武汉）有限公司 | Oca-e单晶及其制备方法和用途 |
| CN106518946A (zh) | 2015-09-10 | 2017-03-22 | 上海迪诺医药科技有限公司 | 磺酰脲衍生物、其药物组合物及应用 |
| GB201608776D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
| GB201608779D0 (en) | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
-
2016
- 2016-05-18 GB GBGB1608777.7A patent/GB201608777D0/en not_active Ceased
-
2017
- 2017-05-18 PT PT177257409T patent/PT3458469T/pt unknown
- 2017-05-18 US US16/302,059 patent/US10968250B2/en active Active
- 2017-05-18 ES ES21160246T patent/ES2970336T3/es active Active
- 2017-05-18 KR KR1020187035834A patent/KR102458265B1/ko active Active
- 2017-05-18 EP EP17725740.9A patent/EP3458469B1/en active Active
- 2017-05-18 AU AU2017266539A patent/AU2017266539B2/en active Active
- 2017-05-18 HR HRP20211128TT patent/HRP20211128T1/hr unknown
- 2017-05-18 EA EA201892514A patent/EA037584B1/ru unknown
- 2017-05-18 EP EP21160246.1A patent/EP3848382B1/en active Active
- 2017-05-18 JP JP2018560597A patent/JP7034093B2/ja active Active
- 2017-05-18 ES ES17725740T patent/ES2878577T3/es active Active
- 2017-05-18 HU HUE17725740A patent/HUE054851T2/hu unknown
- 2017-05-18 CN CN201780030532.1A patent/CN109415407B/zh active Active
- 2017-05-18 MX MX2018014164A patent/MX378591B/es unknown
- 2017-05-18 WO PCT/GB2017/051385 patent/WO2017199033A1/en not_active Ceased
-
2021
- 2021-02-26 US US17/186,272 patent/US11479577B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2666098C (en) | Preparation of nucleosides ribofuranosyl pyrimidines | |
| JP2003528828A5 (enExample) | ||
| RU2017114156A (ru) | N-ацетилгалактозаминовые (galnac) фосфорамитиды, их конъюгаты с нуклеиновыми кислотами и их применение | |
| JP2012503621A5 (enExample) | ||
| JP2007530450A5 (enExample) | ||
| JPH11315072A5 (enExample) | ||
| CA2454306A1 (en) | Substituted dihydro 3-halo-1h-pyrazole-5-carboxylates their preparation and use | |
| JP2010500343A5 (enExample) | ||
| RU2018143237A (ru) | Катионный липид | |
| JP2002539152A5 (enExample) | ||
| ES2878577T3 (es) | Intermedios para la síntesis de derivados del ácido biliar, en particular del ácido obeticólico | |
| JP2017534669A5 (enExample) | ||
| JP2010132690A (ja) | ２−（６−置換−１，３−ジオキサン−４−イル）酢酸誘導体の製造方法 | |
| JP2010532365A5 (enExample) | ||
| JP2019516729A5 (enExample) | ||
| JP2012532894A5 (enExample) | ||
| EP0818460A2 (de) | Festphasensynthese von Oligonucleotiden | |
| JP2004529953A5 (enExample) | ||
| KR960703887A (ko) | 쿠마린 및 카르보스티릴을 pla₂- 억제제로서 사용하는 방법, 및 쿠마린 및 카르보스티릴, 및 이것들의 제조 방법 및 이것들을 함유하는 약제(use of coumarins and carbostyrils as pla₂-inhibitors. new coumarins and car-bostyrils. process for preparing the same and medica-ments) | |
| SI2576565T1 (en) | Synthesis of carbanucleoside and its new useful intermediates | |
| ATE475653T1 (de) | Verfahren zur herstellung von valsartan | |
| RU97112894A (ru) | Производные 10-деацетил-14бета-гидроксибаккатина iii, способ их получения и композиции, содержащие эти соединения | |
| RU2003114754A (ru) | Способ получения бисбензазолиловых соединений | |
| KR840004726A (ko) | 5-하이드록시트립타민 길항제인 퀴놀린 유도체의 제조방법 및 그 제약조성물 | |
| Schrempp et al. | Synthesis of α‐Chiral Butyrolactones by Highly Stereoselective Radical Transfer or Sequential Asymmetric Alkylations: Concise Preparation of Leupyrrin Moieties |